Literature DB >> 15988578

Implantation of primary cultured adipocytes that secrete insulin modifies blood glucose levels in diabetic mice.

M Ito1, H Bujo, K Takahashi, T Arai, I Tanaka, Y Saito.   

Abstract

AIM/HYPOTHESIS: In type 1 diabetic patients, basal insulin supplementation plays a central role in tight glycaemic control. Therefore, safe and steady supplementation of basal insulin is strongly desirable, despite the need for multiple injections. The aim of this study was to investigate a procedure for supplementation using genetically engineered, primary-cultured adipocytes in diabetic mice.
METHODS: Furin-cleavable human proinsulin cDNA was transferred into murine primary-cultured adipocytes using a retroviral vector. The cells were implanted subcutaneously into streptozotocin-induced diabetic mice.
RESULTS: The transfected cells secreted substantial amounts of mature insulin, as well as C-peptide, into conditioned medium. Syngeneic implantation of the cells significantly improved hyperglycaemia and blood HbA(1)c concentrations in a manner that was dependent on cell number, without causing hypoglycaemia. The plasma insulin concentration was dependent on the implanted cell number, and the systemic effect of the circulating insulin was confirmed by marked improvement of body weight reduction and liver glycogen content. Additionally, surgical resection of the implants, in which the insulin secretion was immunologically confirmed after transplantation, diminished the glucose-lowering effect, suggesting that in vivo expression could be eliminated if necessary. CONCLUSIONS/
INTERPRETATION: These results indicate that the autotransplantation of functionalised adipocytes may lead to a clinical application in the treatment of diabetes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15988578     DOI: 10.1007/s00125-005-1825-0

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  26 in total

1.  Ceiling culture of mature human adipocytes: use in studies of adipocyte functions.

Authors:  H H Zhang; S Kumar; A H Barnett; M C Eggo
Journal:  J Endocrinol       Date:  2000-02       Impact factor: 4.286

2.  Prevention of vascular and neural dysfunction in diabetic rats by C-peptide.

Authors:  Y Ido; A Vindigni; K Chang; L Stramm; R Chance; W F Heath; R D DiMarchi; E Di Cera; J R Williamson
Journal:  Science       Date:  1997-07-25       Impact factor: 47.728

Review 3.  Prospects for insulin delivery by ex-vivo somatic cell gene therapy.

Authors:  C J Bailey; E L Davies; K Docherty
Journal:  J Mol Med (Berl)       Date:  1999-01       Impact factor: 4.599

4.  Hepatic insulin gene expression as treatment for type 1 diabetes mellitus in rats.

Authors:  P Muzzin; R C Eisensmith; K C Copeland; S L Woo
Journal:  Mol Endocrinol       Date:  1997-06

5.  Primary cultures of unilocular fat cells: characteristics of growth in vitro and changes in differentiation properties.

Authors:  H Sugihara; N Yonemitsu; S Miyabara; K Yun
Journal:  Differentiation       Date:  1986       Impact factor: 3.880

6.  Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin.

Authors:  J Rosenstock; S L Schwartz; C M Clark; G D Park; D W Donley; M B Edwards
Journal:  Diabetes Care       Date:  2001-04       Impact factor: 19.112

7.  Effects of C-peptide on renal function at the early stage of experimental diabetes.

Authors:  M Sjöquist; W Huang; B L Johansson
Journal:  Kidney Int       Date:  1998-09       Impact factor: 10.612

8.  Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity.

Authors:  I Shimomura; T Funahashi; M Takahashi; K Maeda; K Kotani; T Nakamura; S Yamashita; M Miura; Y Fukuda; K Takemura; K Tokunaga; Y Matsuzawa
Journal:  Nat Med       Date:  1996-07       Impact factor: 53.440

9.  Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. The European Study Group of HOE 901 in type 1 diabetes.

Authors:  T R Pieber; I Eugène-Jolchine; E Derobert
Journal:  Diabetes Care       Date:  2000-02       Impact factor: 19.112

10.  Positional cloning of the mouse obese gene and its human homologue.

Authors:  Y Zhang; R Proenca; M Maffei; M Barone; L Leopold; J M Friedman
Journal:  Nature       Date:  1994-12-01       Impact factor: 49.962

View more
  5 in total

1.  Receptor-mediated oral delivery of a bioencapsulated green fluorescent protein expressed in transgenic chloroplasts into the mouse circulatory system.

Authors:  Arati Limaye; Vijay Koya; Mohtashem Samsam; Henry Daniell
Journal:  FASEB J       Date:  2006-04-07       Impact factor: 5.191

2.  Fibrin glue increases the cell survival and the transduced gene product secretion of the ceiling culture-derived adipocytes transplanted in mice.

Authors:  Yasuyuki Aoyagi; Masayuki Kuroda; Sakiyo Asada; Hideaki Bujo; Shigeaki Tanaka; Shunichi Konno; Masami Tanio; Itsuko Ishii; Masayuki Aso; Yasushi Saito
Journal:  Exp Mol Med       Date:  2011-03-31       Impact factor: 8.718

3.  LCAT-trial-24 weeks: Protocol for a clinical study to evaluate the safety of regenerative medicine and gene therapy by the autologous transplantation of human lecithin:cholesterol acyltransferase gene-transduced human pre-adipocytes.

Authors:  Masayuki Kuroda; Makoto Hori; Yoshiro Maezawa; Yoshitaka Kubota; Nobuyuki Mitsukawa; Yuki Shiko; Yoshihito Ozawa; Yohei Kawasaki; Yasushi Saito; Hideki Hanaoka; Koutaro Yokote
Journal:  Contemp Clin Trials Commun       Date:  2022-06-09

Review 4.  Adipocytes as a vehicle for ex vivo gene therapy: Novel replacement therapy for diabetes and other metabolic diseases.

Authors:  Masayuki Kuroda; Hideaki Bujo; Masayuki Aso; Yasushi Saito
Journal:  J Diabetes Investig       Date:  2011-10-07       Impact factor: 4.232

Review 5.  Adipocyte-Based Cell Therapy in Oncology: The Role of Cancer-Associated Adipocytes and Their Reinterpretation as Delivery Platforms.

Authors:  Raluca Munteanu; Anca Onaciu; Cristian Moldovan; Alina-Andreea Zimta; Diana Gulei; Angelo V Paradiso; Vladimir Lazar; Ioana Berindan-Neagoe
Journal:  Pharmaceutics       Date:  2020-04-28       Impact factor: 6.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.